Venlafaxine Hydrochloride side effects: what 131,548 FDA adverse event reports show
Drug class
Not stated in label
Who reports
131,548 reports · 74% serious · 13,161 with death outcome · 72% female
Used for
Venlafaxine extended-release tablets are a selective serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for: Major Depressive Disorder (MDD) ( 1.1 ) Social Anxiety Disorder (SAD) ( 1.2 ) 1.1 Major Depressive Disorder Venlafaxine extended-release tablets are indicated for the treatment of major depressive disorder (MDD).
What it is
Venlafaxine is a tertiary amino compound that is N,N-dimethylethanamine substituted at position 1 by a 1-hydroxycyclohexyl and 4-methoxyphenyl group.
Boxed warning
WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of Major Depressive Disorder (MDD) and other psychiatric disorders.
Causality screen of the 40 strongest signals
What the badges mean
- Labeled — boxed warning The term (or its clinical synonym) appears in the FDA boxed warning: causality is regulator-recognised and considered serious.
- Labeled adverse reaction The exact term appears in the label's warnings or adverse-reactions sections: a known, expected effect. The FAERS signal confirms the label rather than discovering anything.
- Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
- Likely indication confounding The term appears in the label's indications: reports probably describe the disease being treated (or its progression), not a drug effect. Classic confounding by indication.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,153 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Inspiratory capacity decreased | 101 | 92.3 72.2–118.0ROR 92.4 · calibrated p 3e-7 ✓ | 57.8 EB05 48.9 · IC025 +5.2 3/3 methods agree | Not in label — unassessed | serious n=101 · ♀ 0% (drug 72%) · 100% clinician | no trial arm names this drug |
| Amaurosis fugax | 222 | 41.6 35.9–48.2ROR 41.7 · calibrated p 4e-5 ✓ | 33.0 EB05 29.5 · IC025 +4.7 3/3 methods agree | Not in label — unassessed | serious n=222 · 100% clinician | no trial arm names this drug |
| Temperature regulation disorder | 335 | 28.7 25.6–32.3ROR 28.8 · calibrated p 3e-4 ✓ | 24.4 EB05 22.3 · IC025 +4.4 3/3 methods agree | Not in label — unassessed | serious n=328 · ♀ 100% (drug 72%) | no trial arm names this drug |
| Feelings of worthlessness | 184 | 25.8 22.0–30.1ROR 25.8 · calibrated p 6e-4 ✓ | 22.2 EB05 19.7 · IC025 +4.2 3/3 methods agree | Likely indication confounding term in indications | 73% consumer | no trial arm names this drug |
| Respiratory disorder neonatal | 222 | 25.7 22.3–29.6ROR 25.8 · calibrated p 6e-4 ✓ | 22.2 EB05 19.8 · IC025 +4.2 3/3 methods agree | Not in label — unassessed | serious n=222 · ♀ 35% (drug 72%) | no trial arm names this drug |
| Selective eating disorder | 127 | 25.7 21.3–31.0ROR 25.7 · calibrated p 6e-4 ✓ | 22.2 EB05 19.1 · IC025 +4.1 3/3 methods agree | Labeled (related wording) related wording | serious n=126 · 100% clinician | no trial arm names this drug |
| Serotonin syndrome | 2,520 | 24.1 23.1–25.1ROR 24.5 · calibrated p 7e-4 ✓ | 21.0 EB05 20.3 · IC025 +4.3 3/3 methods agree | Labeled — boxed warning exact term | age-adj. PRR 17.0 · serious PRR 16.3 | no trial arm names this drug |
| Hypotonia neonatal | 193 | 22.9 19.7–26.6ROR 22.9 · calibrated p 0.001 ✓ | 20.1 EB05 17.8 · IC025 +4.0 3/3 methods agree | Not in label — unassessed | serious n=193 · 100% clinician | no trial arm names this drug |
| Feeling guilty | 158 | 21.4 18.2–25.3ROR 21.5 · calibrated p 0.002 ✓ | 18.9 EB05 16.6 · IC025 +3.9 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | 100% consumer | no trial arm names this drug |
| Physical deconditioning | 298 | 21.4 19.0–24.2ROR 21.5 · calibrated p 0.001 ✓ | 18.9 EB05 17.2 · IC025 +4.0 3/3 methods agree | Not in label — unassessed | serious n=298 | no trial arm names this drug |
| Bradycardia neonatal | 146 | 21.0 17.6–24.9ROR 21.0 · calibrated p 0.002 ✓ | 18.6 EB05 16.2 · IC025 +3.9 3/3 methods agree | Not in label — unassessed | serious n=146 · 100% clinician | no trial arm names this drug |
| Agitation neonatal | 109 | 20.5 16.8–25.0ROR 20.5 · calibrated p 0.002 ✓ | 18.2 EB05 15.5 · IC025 +3.8 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious n=108 · ♀ 0% (drug 72%) · 100% clinician | no trial arm names this drug |
| Cataplexy | 163 | 20.4 17.4–24.0ROR 20.5 · calibrated p 0.002 ✓ | 18.1 EB05 15.9 · IC025 +3.9 3/3 methods agree | Not in label — unassessed | serious n=139 | no trial arm names this drug |
| Major depression | 745 | 18.0 16.6–19.4ROR 18.1 · calibrated p 0.003 ✓ | 16.2 EB05 15.2 · IC025 +3.9 3/3 methods agree | Labeled (related wording) related wording | serious PRR 12.9 | no trial arm names this drug |
| Electric shock sensation | 251 | 16.3 14.3–18.6ROR 16.4 · calibrated p 0.005 ✓ | 14.9 EB05 13.4 · IC025 +3.6 3/3 methods agree | Labeled adverse reaction exact term | serious n=206 · 75% consumer | no trial arm names this drug |
| Bezoar | 113 | 14.2 11.7–17.2ROR 14.2 · calibrated p 0.009 ✓ | 13.0 EB05 11.1 · IC025 +3.3 3/3 methods agree | Not in label — unassessed | serious n=113 · ♀ 100% (drug 72%) · 100% clinician | no trial arm names this drug |
| Poisoning deliberate | 740 | 13.7 12.7–14.8ROR 13.8 · calibrated p 0.010 ✓ | 12.7 EB05 11.9 · IC025 +3.5 3/3 methods agree | Not in label — unassessed | serious PRR 9.8 · 100% clinician | no trial arm names this drug |
| Foetal death | 388 | 12.8 11.6–14.2ROR 12.9 · calibrated p 0.013 ✓ | 11.9 EB05 10.9 · IC025 +3.4 3/3 methods agree | Not in label — unassessed | serious n=388 · ♀ 100% (drug 72%) | no trial arm names this drug |
| Hyperreflexia | 245 | 11.9 10.5–13.6ROR 12.0 · calibrated p 0.017 ✓ | 11.1 EB05 10.0 · IC025 +3.2 3/3 methods agree | Labeled adverse reaction exact term | serious n=243 · 100% clinician | no trial arm names this drug |
| Emotional poverty | 114 | 11.0 9.1–13.3ROR 11.0 · calibrated p 0.024 ✓ | 10.2 EB05 8.7 · IC025 +3.0 3/3 methods agree | Not in label — unassessed | serious n=110 · ♀ 0% (drug 72%) · 100% consumer | no trial arm names this drug |
| Sleep paralysis | 94 | 10.9 8.8–13.4ROR 10.9 · calibrated p 0.025 ✓ | 10.0 EB05 8.4 · IC025 +2.9 3/3 methods agree | Labeled (related wording) related wording | ♀ 100% (drug 72%) · 100% consumer | no trial arm names this drug |
| Derealisation | 134 | 10.6 8.9–12.6ROR 10.6 · calibrated p 0.027 ✓ | 9.8 EB05 8.5 · IC025 +3.0 3/3 methods agree | Not in label — unassessed | serious n=125 · 100% consumer | no trial arm names this drug |
| Reversible cerebral vasoconstriction syndrome | 118 | 10.1 8.4–12.2ROR 10.1 · calibrated p 0.032 ✓ | 9.4 EB05 8.0 · IC025 +2.9 3/3 methods agree | Not in label — unassessed | serious n=118 · ♀ 100% (drug 72%) · 100% clinician | no trial arm names this drug |
| Hostility | 154 | 10.1 8.6–11.9ROR 10.1 · calibrated p 0.032 ✓ | 9.4 EB05 8.2 · IC025 +3.0 3/3 methods agree | Labeled adverse reaction exact term | serious n=135 | no trial arm names this drug |
| Personality disorder | 158 | 10.1 8.6–11.9ROR 10.1 · calibrated p 0.032 ✓ | 9.4 EB05 8.2 · IC025 +3.0 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious n=149 | no trial arm names this drug |
| Clonus | 164 | 10.1 8.6–11.8ROR 10.1 · calibrated p 0.032 ✓ | 9.4 EB05 8.2 · IC025 +3.0 3/3 methods agree | Labeled adverse reaction exact term | serious n=161 · 100% clinician | no trial arm names this drug |
| Negative thoughts | 173 | 9.9 8.5–11.5ROR 9.9 · calibrated p 0.034 ✓ | 9.3 EB05 8.1 · IC025 +2.9 3/3 methods agree | Not in label — unassessed | serious n=87 · 100% consumer | no trial arm names this drug |
| Anorgasmia | 158 | 9.8 8.3–11.5ROR 9.8 · calibrated p 0.036 ✓ | 9.1 EB05 8.0 · IC025 +2.9 3/3 methods agree | Labeled adverse reaction exact term | serious n=127 · 100% consumer | no trial arm names this drug |
| Homicidal ideation | 235 | 9.7 8.5–11.1ROR 9.7 · calibrated p 0.036 ✓ | 9.1 EB05 8.2 · IC025 +3.0 3/3 methods agree | Labeled adverse reaction exact term | serious n=230 | no trial arm names this drug |
| Food allergy | 434 | 9.7 8.8–10.6ROR 9.7 · calibrated p 0.036 ✓ | 9.1 EB05 8.4 · IC025 +3.0 3/3 methods agree | Not in label — unassessed | serious n=422 · ♀ 100% (drug 72%) | no trial arm names this drug |
| Small for dates baby | 283 | 9.5 8.5–10.8ROR 9.6 · calibrated p 0.038 ✓ | 9.0 EB05 8.1 · IC025 +3.0 3/3 methods agree | Not in label — unassessed | serious n=283 | no trial arm names this drug |
| Urinary tract disorder | 245 | 9.1 8.0–10.4ROR 9.1 · calibrated p 0.044 ✓ | 8.6 EB05 7.7 · IC025 +2.9 3/3 methods agree | Not in label — unassessed | serious n=241 · ♀ 0% (drug 72%) | no trial arm names this drug |
| Mydriasis | 682 | 8.9 8.2–9.6ROR 8.9 · calibrated p 0.047 ✓ | 8.4 EB05 7.9 · IC025 +2.9 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 7.9 | no trial arm names this drug |
| Suicide attempt | 3,232 | 8.9 8.6–9.2ROR 9.1 · calibrated p 0.044 ✓ | 8.5 EB05 8.2 · IC025 +3.0 3/3 methods agree | Labeled — boxed warning synonym match | age-adj. PRR 6.6 · serious PRR 6.6 | no trial arm names this drug |
| Hypomania | 196 | 8.9 7.7–10.3ROR 8.9 · calibrated p 0.049 ✓ | 8.4 EB05 7.4 · IC025 +2.8 3/3 methods agree | Labeled — boxed warning exact term | serious n=184 | no trial arm names this drug |
| Withdrawal syndrome | 2,166 | 8.6 8.2–8.9ROR 8.7 · calibrated p 0.051 | 8.2 EB05 7.9 · IC025 +3.0 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 7.9 · serious PRR 6.2 | no trial arm names this drug |
| Psychomotor retardation | 142 | 8.5 7.2–10.1ROR 8.5 · calibrated p 0.057 | 8.0 EB05 6.9 · IC025 +2.7 3/3 methods agree | Likely indication confounding term in indications | serious n=140 · 100% clinician | no trial arm names this drug |
| Tearfulness | 217 | 8.4 7.3–9.6ROR 8.4 · calibrated p 0.059 | 7.9 EB05 7.1 · IC025 +2.8 3/3 methods agree | Not in label — unassessed | serious n=196 | no trial arm names this drug |
| Gestational diabetes | 236 | 8.4 7.3–9.5ROR 8.4 · calibrated p 0.058 | 7.9 EB05 7.1 · IC025 +2.8 3/3 methods agree | Not in label — unassessed | serious n=233 · ♀ 100% (drug 72%) | no trial arm names this drug |
| Atrial septal defect | 419 | 8.3 7.5–9.2ROR 8.3 · calibrated p 0.059 | 7.9 EB05 7.3 · IC025 +2.8 3/3 methods agree | Not in label — unassessed | serious PRR 6.2 | no trial arm names this drug |
Clinical concept groups
MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.
| Concept | Reports | PRR 95% CI | Reading |
|---|---|---|---|
| Suicidality | 11,167 | 7.57.4–7.7 | signal |
| Depression | 8,154 | 4.74.6–4.8 | signal |
| Extrapyramidal | 2,376 | 3.73.5–3.8 | signal |
| Dependence / withdrawal | 6,558 | 3.63.5–3.7 | signal |
| Hyponatraemia | 1,411 | 2.82.7–3.0 | signal |
| Seizure | 3,275 | 2.72.6–2.8 | signal |
| Arrhythmia / qt | 2,584 | 2.12.1–2.2 | signal |
| Fall / fracture | 4,978 | 2.12.0–2.2 | signal |
| Rhabdomyolysis / myopathy | 1,040 | 2.11.9–2.2 | raised |
| Pancreatitis | 1,022 | 2.01.9–2.2 | raised |
| Hyperglycaemia / diabetes | 3,312 | 1.51.5–1.6 | raised |
| Hypoglycaemia | 912 | 1.51.4–1.6 | raised |
| Liver injury | 2,845 | 1.51.5–1.6 | raised |
| Kidney injury | 4,012 | 1.41.4–1.4 | raised |
| Tendon disorder | 319 | 1.31.2–1.5 | raised |
| Venous thromboembolism | 1,756 | 1.31.2–1.4 | raised |
Trial evidence (ClinicalTrials.gov)
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Drug ineffective (drug did not work) | 9,998 | 1.2 1.2–1.2ROR 1.2 · calibrated p 0.460 | 1.2 EB05 1.2 · IC025 +0.2 | Reporting / coding artifact | age-adj. PRR 1.4 · serious PRR 1.7 | no trial arm names this drug |
| Nausea | 9,124 | 1.9 1.8–1.9ROR 1.9 · calibrated p 0.898 | 1.8 EB05 1.8 · IC025 +0.8 | Labeled adverse reaction exact term | age-adj. PRR 1.5 · serious PRR 1.9 | no trial arm names this drug |
| Fatigue (tiredness) | 8,204 | 1.7 1.7–1.7ROR 1.7 · calibrated p 0.792 | 1.7 EB05 1.7 · IC025 +0.7 | Likely indication confounding term in indications; also in warnings | age-adj. PRR 1.5 · serious PRR 1.7 | no trial arm names this drug |
| Headache | 7,506 | 1.9 1.9–2.0ROR 2.0 · calibrated p 0.932 | 1.9 EB05 1.9 · IC025 +0.9 | Labeled adverse reaction exact term | age-adj. PRR 1.6 · serious PRR 2.2 | no trial arm names this drug |
| Dizziness | 6,591 | 2.1 2.1–2.2ROR 2.2 · calibrated p 0.959 | 2.1 EB05 2.1 · IC025 +1.0 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 1.8 · serious PRR 2.1 | no trial arm names this drug |
| Depression | 6,352 | 4.5 4.4–4.6ROR 4.7 · calibrated p 0.268 | 4.4 EB05 4.3 · IC025 +2.1 3/3 methods agree | Labeled — boxed warning exact term | age-adj. PRR 3.8 · serious PRR 3.9 | no trial arm names this drug |
| Anxiety | 6,172 | 3.5 3.4–3.6ROR 3.6 · calibrated p 0.455 | 3.4 EB05 3.4 · IC025 +1.7 3/3 methods agree | Likely indication confounding term in indications; also in warnings | age-adj. PRR 3.0 · serious PRR 3.1 | no trial arm names this drug |
| Off label use (used outside approved label) | 6,108 | 1.1 1.1–1.2ROR 1.1 · calibrated p 0.392 | 1.1 EB05 1.1 · IC025 +0.1 | Reporting / coding artifact | age-adj. PRR 1.1 · serious PRR 1.3 | no trial arm names this drug |
| Pain | 5,568 | 1.4 1.4–1.5ROR 1.5 · calibrated p 0.619 | 1.4 EB05 1.4 · IC025 +0.5 | Labeled adverse reaction exact term | age-adj. PRR 1.4 · serious PRR 1.4 | no trial arm names this drug |
| Diarrhoea (diarrhea) | 5,300 | 1.3 1.3–1.4ROR 1.3 · calibrated p 0.528 | 1.3 EB05 1.3 · IC025 +0.3 | Labeled adverse reaction exact term | age-adj. PRR 1.2 · serious PRR 1.3 | no trial arm names this drug |
| Vomiting | 4,917 | 1.7 1.6–1.7ROR 1.7 · calibrated p 0.772 | 1.7 EB05 1.6 · IC025 +0.7 | Labeled adverse reaction exact term | age-adj. PRR 1.4 · serious PRR 1.5 | no trial arm names this drug |
| Insomnia (trouble sleeping) | 4,866 | 2.9 2.9–3.0ROR 3.0 · calibrated p 0.620 | 2.9 EB05 2.8 · IC025 +1.5 3/3 methods agree | Likely indication confounding term in indications; also in warnings | age-adj. PRR 2.4 · serious PRR 3.0 | no trial arm names this drug |
| Fall | 4,751 | 2.3 2.2–2.4ROR 2.3 · calibrated p 0.882 | 2.3 EB05 2.2 · IC025 +1.1 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 2.2 · serious PRR 1.9 | no trial arm names this drug |
| Toxicity to various agents | 4,672 | 4.5 4.4–4.7ROR 4.7 · calibrated p 0.274 | 4.4 EB05 4.3 · IC025 +2.1 3/3 methods agree | Not in label — unassessed | age-adj. PRR 4.1 · serious PRR 3.5 · 94% clinician | no trial arm names this drug |
| Dyspnoea (shortness of breath) | 4,580 | 1.3 1.3–1.3ROR 1.3 · calibrated p 0.510 | 1.3 EB05 1.3 · IC025 +0.3 | Labeled adverse reaction exact term | age-adj. PRR 1.2 · serious PRR 1.2 | no trial arm names this drug |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Inspiratory capacity decreased — n=101, PRR 92.3
- Amaurosis fugax — n=222, PRR 41.6
- Temperature regulation disorder — n=335, PRR 28.7
- Respiratory disorder neonatal — n=222, PRR 25.7
- Hypotonia neonatal — n=193, PRR 22.9
- Physical deconditioning — n=298, PRR 21.4
- Bradycardia neonatal — n=146, PRR 21.0
- Cataplexy — n=163, PRR 20.4
- Bezoar — n=113, PRR 14.2
- Poisoning deliberate — n=740, PRR 13.7
✓ A hand-written Bradford Hill causality assessment exists for this drug: Venlafaxine (serotonergic antidepressants) ↔ Serotonin syndrome.
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Venlafaxine?
In FDA FAERS, the most frequently co-reported reaction terms for Venlafaxine are nausea, fatigue, headache, dizziness, depression, anxiety. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Venlafaxine have an FDA boxed warning?
Yes. The current FDA label carries a boxed warning: WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of Major Depressive Disorder (MDD) and other psychiatric disorders.
Do FAERS signals prove that Venlafaxine causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 14b38374-7287-47dd-8ef9-e88bd5b23a26, effective 20241130; matched on
openfda.generic_name.exact:"VENLAFAXINE" AND openfda.product_type:"HUMAN PRESCRIPTION DRUG") - PubChem CID 5656 description (ChEBI)
- Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,193 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
VENLAFAXINE, results-bearing studies sorted by enrollment)
Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.